CY1108452T1 - ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ ΩΣ ΠΕΡΙΦΕΡΙΚΩΣ ΕΚΛΕΚΤΙΚΩΝ ΑΝΑΣΤΟΛΕΩΝ ΤΗΣ ΝΤΟΠΑΜΙΝΗΣ-β-ΥΔΡΟΞΥΛΑΣΗΣ - Google Patents

ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ ΩΣ ΠΕΡΙΦΕΡΙΚΩΣ ΕΚΛΕΚΤΙΚΩΝ ΑΝΑΣΤΟΛΕΩΝ ΤΗΣ ΝΤΟΠΑΜΙΝΗΣ-β-ΥΔΡΟΞΥΛΑΣΗΣ

Info

Publication number
CY1108452T1
CY1108452T1 CY20081101204T CY081101204T CY1108452T1 CY 1108452 T1 CY1108452 T1 CY 1108452T1 CY 20081101204 T CY20081101204 T CY 20081101204T CY 081101204 T CY081101204 T CY 081101204T CY 1108452 T1 CY1108452 T1 CY 1108452T1
Authority
CY
Cyprus
Prior art keywords
hydroxylum
dopopamin
imidazoli
extractive
inhibitors
Prior art date
Application number
CY20081101204T
Other languages
English (en)
Inventor
David Alexander Learmonth
Da Silva Patricio Manuel Viera Araujo Soares
Alexander Beliaev
Original Assignee
Bial - Portela & Ca., S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03256420A external-priority patent/EP1408038B1/en
Application filed by Bial - Portela & Ca., S.A. filed Critical Bial - Portela & Ca., S.A.
Publication of CY1108452T1 publication Critical patent/CY1108452T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Περιγράφονται ενώσεις του τύπου Ι και μέθοδος παρασκευής αυτών όπου Χ είναι CH2, Ο ή S, και n είναι 1, 2 ή 3, υπό την προϋπόθεση ότι, όταν το Χ είναι CH2, το n δεν είναι 1. Οι ενώσεις έχουν δυνάμει πολύτιμες φαρμακευτικές ιδιότητες για την θεραπεία καρδιοαγγειακών διαταραχών όπως είναι η υπέρταση και η χρόνια καρδιακή ανεπάρκεια.
CY20081101204T 2002-10-11 2008-10-24 ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ ΩΣ ΠΕΡΙΦΕΡΙΚΩΣ ΕΚΛΕΚΤΙΚΩΝ ΑΝΑΣΤΟΛΕΩΝ ΤΗΣ ΝΤΟΠΑΜΙΝΗΣ-β-ΥΔΡΟΞΥΛΑΣΗΣ CY1108452T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0223719A GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0224306A GB2394223B (en) 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
EP03256420A EP1408038B1 (en) 2002-10-11 2003-10-10 Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase

Publications (1)

Publication Number Publication Date
CY1108452T1 true CY1108452T1 (el) 2014-04-09

Family

ID=9945777

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20081101204T CY1108452T1 (el) 2002-10-11 2008-10-24 ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟΛΙΟΥ ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ ΩΣ ΠΕΡΙΦΕΡΙΚΩΣ ΕΚΛΕΚΤΙΚΩΝ ΑΝΑΣΤΟΛΕΩΝ ΤΗΣ ΝΤΟΠΑΜΙΝΗΣ-β-ΥΔΡΟΞΥΛΑΣΗΣ
CY20111100639T CY1112457T1 (el) 2002-10-11 2011-07-01 Χρωμανο- και θειοxρωμανο-3-υλο-1,3-διυδρο-ιμιδαζολια ως αναστολεις της ντοπαμινο-β-υδροξυλασης, και μεθοδοι παρασκευης αυτων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100639T CY1112457T1 (el) 2002-10-11 2011-07-01 Χρωμανο- και θειοxρωμανο-3-υλο-1,3-διυδρο-ιμιδαζολια ως αναστολεις της ντοπαμινο-β-υδροξυλασης, και μεθοδοι παρασκευης αυτων

Country Status (11)

Country Link
KR (1) KR101350741B1 (el)
CN (1) CN100393715C (el)
AR (2) AR041589A1 (el)
AT (5) ATE500248T1 (el)
CY (2) CY1108452T1 (el)
DE (4) DE60336772D1 (el)
DK (2) DK1408038T3 (el)
ES (5) ES2384118T3 (el)
GB (2) GB2393958A (el)
HK (1) HK1116188A1 (el)
SI (2) SI1408038T1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
CN103380128B (zh) * 2010-12-22 2017-03-01 拜欧波尔特拉及正大有限公司 晶型及其制备方法
GB201316410D0 (en) * 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82401A0 (en) * 1986-05-06 1987-11-30 Merrell Dow Pharma Dopamine beta hydroxy-lase inhibiting imidazole derivatives and pharmaceutical compositions containing them
US4868210A (en) 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
EP0757677B1 (en) * 1994-04-26 2003-06-18 Syntex (U.S.A.) LLC Benzocyclohexylimidazolethione derivatives

Also Published As

Publication number Publication date
AR095674A2 (es) 2015-11-04
DE60336275D1 (de) 2011-04-14
ES2364919T3 (es) 2011-09-16
ATE500248T1 (de) 2011-03-15
ATE550335T1 (de) 2012-04-15
SI1908760T1 (sl) 2011-05-31
CY1112457T1 (el) 2015-12-09
GB0223719D0 (en) 2002-11-20
ES2384118T3 (es) 2012-06-29
DK1408038T3 (da) 2008-11-24
GB2394223A (en) 2004-04-21
GB2393958A (en) 2004-04-14
DK1908760T3 (da) 2011-07-25
GB2394223B (en) 2007-05-16
DE60336772D1 (de) 2011-05-26
ATE500247T1 (de) 2011-03-15
DE60336276D1 (de) 2011-04-14
ATE505465T1 (de) 2011-04-15
CN100393715C (zh) 2008-06-11
ES2309279T3 (es) 2008-12-16
KR20120038014A (ko) 2012-04-20
ES2361938T3 (es) 2011-06-24
ATE403652T1 (de) 2008-08-15
ES2361939T3 (es) 2011-06-24
AR041589A1 (es) 2005-05-26
KR101350741B1 (ko) 2014-01-10
SI1408038T1 (sl) 2008-10-31
CN1726211A (zh) 2006-01-25
HK1116188A1 (en) 2008-12-19
GB0224306D0 (en) 2002-11-27
DE60322642D1 (de) 2008-09-18

Similar Documents

Publication Publication Date Title
CY1108041T1 (el) Αναστολεις της rho-κινασης
CY1117217T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
CY1107475T1 (el) Αναστολεις ρο-κινασης
EA200401398A1 (ru) Замещённые фенилацетамиды и их применение в качестве активаторов глюкокиназы
EA200100826A1 (ru) 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике
EA200500856A1 (ru) Новые химические соединения
ATE357434T1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
CY1107985T1 (el) Ccr1 ανταγωνιστες για την αγωγη μεταξυ αλλων απομυελινωτικης φλεγμονωδους νοσου
ATE447562T1 (de) Verstärker von glutamat-rezeptoren
DE60318177D1 (de) Rho-kinase inhibitoren
CY1105617T1 (el) Νεα αρωματικα παραγωγα των φθορογλυκοσιδων, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους
CY1113757T1 (el) Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων
BR0307432B1 (pt) difluormetiltiazolilcarboxanilidas
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
CY1107871T1 (el) Παραγωγα πυριμιδινης και η χρηση τους ως ρυθμιστων cb2
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
LV12047A (lv) Kondenseti pirimidina atvasinajumi un to lietosana par angiotenzina II antagonistiem
CY1109214T1 (el) Μειγματα μυκητοκτονου που βασιζονται σε παραγωγα καρβαμικου και εντομοκτονα
EA200001133A1 (ru) Антипикорнавирусные композиции, их получение и применение
CY1110537T1 (el) Ενωσεις και μεθοδοι για την αγωγη της δυσλιπιδαιμιας
CY1113171T1 (el) Αντιφλεγμονωδεις παραγοντες
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung